Feasibility and patient-reported satisfaction using a novel point-of-care fingerstick method for monitoring absolute neutrophil count for clozapine.

Deanna L Kelly¹, Olga Y Ponomareva², Marie Mackowick³, Matthew Glassman¹, Jaeboon Park³, Myriam Navarro-De La Vega⁴, Heidi J Wehring¹, Gopal Vyas¹

¹Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland, USA.

²University of Maryland/Sheppard Pratt Psychiatry Residency Training Program, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland, USA.

³Clifton T. Perkins Hospital Center, Jessup, Maryland, USA.

⁴Athelas, Mountain View, California, USA.

PubMed DOI

Abstract

BACKGROUND: Clozapine is an effective antipsychotic for treatment-resistant schizophrenia. One limitation of clozapine use is required monitoring of absolute neutrophil count (ANC) because of the risk of clozapine-induced neutropenia. Standard monitoring requires venous blood draws, which is a significant barrier to clozapine use. METHODS: This study assesses the feasibility of use and physician…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.